1型糖尿病中对氧化翻译后修饰胰岛素新抗原肽的自身抗体和T细胞反应
研究鉴定出三种经LC-MS/MS确认的胰岛素肽段(Nt-INSP-3、Nt-INSP-4、Nt-INSP-6),并评估其氧化形式对1型糖尿病患者抗体和T细胞反应的刺激能力。结果显示Nt-INSP-4和Nt-INSP-6的血清抗体结合在1型糖尿病中较健康对照更强(p≤0.02),氧化型ERGFFYTPKT(oxPTM-INSP-6)结合率最高(83%至>88%,p≤0.001 vs 对照)。Nt-INSP-4诱导的CD4+(p<0.001)和CD8+(p=0.049)T细胞刺激在1型糖尿病中最强,44.4%患者呈现CD4+、CD8+ T细胞与自身抗体一致的自身免疫反应。
要点
- 在63例新发1型糖尿病和30例对照中,Nt-INSP-4和Nt-INSP-6的血清抗体结合在1型糖尿病中较健康对照更强(p≤0.02)。
- 氧化型ERGFFYTPKT(oxPTM-INSP-6)抗体结合率最高:本室羟自由基修饰肽83%结合,计算机模拟氧化肽>88%结合(p≤0.001 vs 对照)。
- Nt-INSP-4在1型糖尿病中诱导的CD4+(p<0.001)和CD8+(p=0.049)T细胞刺激均强于对照;44.4%患者呈现CD4+、CD8+ T细胞与自身抗体一致的反应。
核心结论
- 研究结果支持氧化应激和胰岛素新抗原表位可能参与1型糖尿病免疫发病机制的概念。
研究设计与样本
- 将胰岛素暴露于多种活性氧化剂生成oxPTM-INS,经尺寸排阻色谱分离后行ELISA和LC-MS/MS鉴定氧化肽新表位。
- 用63例新发1型糖尿病和30例对照的血清以ELISA检测oxPTM-INSPs自身抗体。
- 另用18份新鲜血样(近期诊断1型糖尿病)、5例已确诊1型糖尿病和11例对照,平行评估oxPTM-INSPs对CD4+和CD8+ T细胞的激活。
主要发现
- 在6个LC-MS/MS鉴定的胰岛素肽候选物中,对A:12-21(SLYQLENYCN,Nt-INSP-3)、B:11-30(LVEALYLVCGERGFFYTPKT,Nt-INSP-4)和B:21-30(ERGFFYTPKT,Nt-INSP-6)三个观察到抗体和T细胞反应。
- Nt-INSP-4和Nt-INSP-6的血清抗体结合在1型糖尿病中较健康对照更强(p≤0.02)。
- 氧化型ERGFFYTPKT(oxPTM-INSP-6)抗体结合最高:本室羟自由基(●OH)修饰肽83%结合,计算机模拟氧化肽>88%结合(p≤0.001 vs 对照)。
- Nt-INSP-4在1型糖尿病中诱导的T细胞刺激最强:CD4+ p<0.001,CD8+ p=0.049(均 vs 对照)。
- oxPTM-INSP-6的CD4+反应在1型糖尿病中较对照更常见(66.7% vs 27.3%;p=0.039);1型糖尿病中oxPTM-INSP-6的CD4+反应较Nt-INSP-6更常见(66.7% vs 27.8%;p=0.045)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Antibodies specific to oxidative post-translational modifications (oxPTM) of insulin (oxPTM-INS) are present in most individuals with type 1 diabetes, even before the clinical onset. However, the antigenic determinants of such response are still unknown. In this study, we investigated the antibody response to oxPTM-INS neoepitope peptides (oxPTM-INSPs) and evaluated their ability to stimulate humoral and T cell responses in type 1 diabetes. We also assessed the concordance between antibody and T cell responses to the oxPTM-INS neoantigenic peptides. METHODS: oxPTM-INS was generated by exposing insulin to various reactive oxidants. The insulin fragments resulting from oxPTM were fractionated by size-exclusion chromatography further to ELISA and LC-MS/MS analysis to identify the oxidised peptide neoepitopes. Immunogenic peptide candidates were produced and then modified in house or designed to incorporate in silico-oxidised amino acids during synthesis. Autoantibodies to the oxPTM-INSPs were tested by ELISA using sera from 63 participants with new-onset type 1 diabetes and 30 control participants. An additional 18 fresh blood samples from participants with recently diagnosed type 1 diabetes, five with established disease, and from 11 control participants were used to evaluate, in parallel, CD4+ and CD8+ T cell activation by oxPTM-INSPs. RESULTS: We observed antibody and T cell responses to three out of six LC-MS/MS-identified insulin peptide candidates: A:12-21 (SLYQLENYCN, native insulin peptide 3 [Nt-INSP-3]), B:11-30 (LVEALYLVCGERGFFYTPKT, Nt-INSP-4) and B:21-30 (ERGFFYTPKT, Nt-INSP-6). For Nt-INSP-4 and Nt-INSP-6, serum antibody binding was stronger in type 1 diabetes compared with healthy control participants (p≤0.02), with oxidised forms of ERGFFYTPKT, oxPTM-INSP-6 conferring the highest antibody binding (83% binders to peptide modified in house by hydroxyl radical [●OH] and >88% to in silico-oxidised peptide; p≤0.001 vs control participants). Nt-INSP-4 induced the strongest T cell stimulation in type 1 diabetes compared with control participants for both CD4+ (p<0.001) and CD8+ (p=0.049). CD4+ response to oxPTM-INSP-6 was also commoner in type 1 diabetes than in control participants (66.7% vs 27.3%; p=0.039). Among individuals with type 1 diabetes, the CD4+ response to oxPTM-INSP-6 was more frequent than to Nt-INSP-6 (66.7% vs 27.8%; p=0.045). Overall, 44.4% of patients showed a concordant autoimmune response to oxPTM-INSP involving simultaneously CD4+ and CD8+ T cells and autoantibodies. CONCLUSIONS/INTERPRETATION: Our findings support the concept that oxidative stress, and neoantigenic epitopes of insulin, may be involved in the immunopathogenesis of type 1 diabetes.
引用
- Strollo R, Vinci C, Man YKS, et al. Autoantibody and T cell responses to oxidative post-translationally modified insulin neoantigenic peptides in type 1 diabetes. Diabetologia. 2022. PMID: 36207582. doi:10.1007/s00125-022-05812-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。